Oct 04,2015

BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call

BD(Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2015 earnings conference call on Wednesday, November 4, 2015, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter’s earnings earlier that morning. The webcast of the conference call, along with related slides, will be accessible through BD’s website at www.bd.com/investors and will be available for replay through Wednesday, November 11, 2015.

View Analyst & Ambassador Comments
Go to original news
Oct 05,2015

Tandem Diabetes Care Named Finalist in CONNECT's 28th Annual Most Innovative New Product Awards

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) has been selected as a finalist in CONNECT's Most Innovative New Product Awards for its t:flex® Insulin Pump. For 28 years, CONNECT, an innovation company accelerator in San Diego, California, has celebrated innovation leaders in the local community with this award. The t:flex Pump is one of three finalist products in the Pharmaceutical and Medical Device category.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 05,2015

Nemaura Medical Present Positive Interim Clinical Trial Results of its sugarBEAT® System

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing the sugarBEAT® CGM System as a minimally invasive, wireless continuous glucose monitoring system, announced today that it has conducted a further interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients, and have determined a reduction in MARD from 18% to 11.8%. MARD is the Mean Absolute Relative Difference between finger-stick measurements and CGM sensor glucose values; a lower MARD indicates higher accuracy.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 09,2015

Insulet Corporation to Announce Third Quarter 2015 Financial Results on November 5, 2015

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2015 on November 5, 2015 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Oct 12,2015

LabStyle Innovations to Present New Case Study at 5th EAI International Conference on Wireless Mobile Communication and Healthcare in London on October 15, 2015

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced its Medical Director, Dr. Moshe Kamar, will present a patient case study at MobiHealth's 5th EAI International Conference on Wireless Mobile Communication and Healthcare. Focused on, "Transforming healthcare through innovations in mobile and wireless technologies," the conference will take place in London, England from October 14 - 16, 2015. At 5:20 pm on Thursday, October 15th, Dr. Kamar will deliver his presentation titled, "Smartphone Application for Self Blood Glucose Monitoring & Disease Management - A Case Report."

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 13,2015

Nemaura Medical Announces Filing of Application for FDA Pre-Submission Program for sugarBEAT® System

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally invasive wireless CGM (Continuous Glucose Monitoring) system known as sugarBEAT®, announced today that it has submitted an application under the FDA Pre-submission Program to confirm the Classification of their CGM for the US market.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2015

LabStyle Innovations to Report New Data at Diabetes Technology Meeting On October 22 and 23, 2015

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced Dr. Paul Rosman, who serves on the Company's Scientific Advisory Board, will present a study titled, "Performance of a Smart Phone Linked Blood Glucose Assessment Platform," at the 15th Annual Diabetes Technology Meeting in Bethesda, Maryland. The poster will be presented on Thursday, October 22, 2015 from 4:00pm to 6:30pm and on Friday, October 23, from 4:45pm to 7:15pm.

CONFERENCES

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 28,2015

Senseonics Reports CGM Europe Pivotal Study Results

Senseonics, Incorporated, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, announced it has met its primary effectiveness and safety endpoints of the interim phase of the PRECISE (A Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor) Study. Results from 44 subjects with diabetes demonstrated strong accuracy throughout the entire 90-day continuous wear period with a mean absolute relative difference (MARD) of 11.4% in the 75-400 mg/dL range when compared to YSI blood reference values. The mean absolute difference (MAD) in the <75 mg/dL range was 13.5 mg/dL. Eighty-four percent (84%) of the sensor values were within 20% of the YSI reference. There were no significant adverse events reported related to the Senseonics CGM system.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 29,2015

Tandem Diabetes Care Reports Third Quarter 2015 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:flex® and t:slim G4™ Insulin Pumps, today reported its financial results for the quarter ended September 30, 2015. As of September 30, 2015, the Company had $83.8 million in cash, cash equivalents and short-term investments. For the third quarter of 2015, operating expenses totaled $24.2 million compared to $23.4 million for the same period of 2014.

View Analyst & Ambassador Comments
Go to original news
Oct 29,2015

LabStyle Innovations Reports Dario Blood Glucose Monitor Demonstrates Over 99% Accuracy in New Study

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced results from a recent performance accuracy study of the Dario™ Blood Glucose Monitoring System. Data was presented by Dr. Paul Rosman, who serves on LabStyle's Scientific Advisory Board, at the 15th Annual Diabetes Technology Meeting in Bethesda, Maryland which took place on October 22-23, 2015. The poster titled "Performance of a Smart Phone Linked Blood Glucose Assessment Platform" presented data which showed the Dario™ meets new International Standards Organization (ISO) 2013 performance requirements for accuracy and with excellent precision results.

CLINICAL STUDY

#bgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES